tbuckley/cabot-search huggingface dataset:
Exposure to Violence, Psychosocial Stress, and Asthma
Authors: Jeremy Landeo-Gutierrez, Erick Forno, Gregory E. Miller, Juan C. Celedón
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Over the last two decades, a growing body of evidence has linked chronic psychosocial stress to asthma. Exposure to violence can lead to chronic stress and has received recent attention in the asthma literature, as is a common exposure for people living in urban settings, particularly in the U.S. Improving our understanding of whether and how exposure to chronic stressors causes or worsens asthma could help us gain insights into disease pathogenesis, design public health policies, and develop new interventions.  In this essay, the evidence linking violence or stress to asthma is explored, including recent insights on potential mechanisms, and a discussion on current challenges and future directions. To date, experimental and observational studies support a causal association between chronic stress and worse asthma control, and increasing evidence suggests that pre- or post-natal chronic stress may lead to new-onset asthma. Such evidence supports conducting randomized controlled trials of stress-reduction interventions to improve asthma control in subjects with high chronic stress. On the other hand, more experimental and longitudinal studies are needed to better understand if violence exposure leads to asthma or worse asthma outcomes. Longitudinal studies with assessment of co-exposures and coping mechanisms are key to not only better understand the independent effects of violence or stress on asthma but also to identify factors that could ameliorate or worsen such effects.
Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma
Authors: Makoto Ohno, Juntaro Matsuzaki, Junpei Kawauchi, Yoshiaki Aoki, Junichiro Miura, Satoko Takizawa, Ken Kato, Hiromi Sakamoto, Yuko Matsushita, Masamichi Takahashi, Yasuji Miyakita, Koichi Ichimura, Yoshitaka Narita, Takahiro Ochiya
Journal: JAMA Network Open (2019)

<h3>Importance</h3> A blood-based screening tool for detecting diffuse glioma is necessary to improve clinical outcomes. <h3>Objectives</h3> To establish models using serum microRNAs to distinguish patients with diffuse glioma from control individuals without cancer (the Glioma Index) and to differentiate glioblastoma (GBM), primary central nervous system lymphoma (PCNSL), and metastatic brain tumors (the 3-Tumor Index). <h3>Design, Setting, and Participants</h3> This retrospective, case-control diagnostic study included 157 patients with diffuse glioma and 109 patients with central nervous system (CNS) diseases other than diffuse glioma diagnosed from August 1, 2008, through May 1, 2016, and 314 sex- and age-matched controls without cancer. Samples of patients with diffuse glioma and controls were randomly divided into training and validation set 1, and those of patients with CNS diseases other than diffuse glioma were allocated to an exploratory set. Samples of patients with GBM, PCNSL, and metastatic brain tumors were randomly divided into training and validation set 2. Data were analyzed from April 1, 2018, to March 31, 2019. <h3>Main Outcomes and Measures</h3> The expression of 2565 microRNAs was assessed, and the diagnostic performance was evaluated by calculating the area under the receiver operating characteristics curve (AUC), sensitivity, specificity, and accuracy. <h3>Results</h3> A total of 580 patients were included in the analysis (309 [53.3%] male; median age, 57 years [range, 10-87 years]). In training set 1, 100 patients with diffuse glioma (median age, 56 years [range, 14-87 years]; 55 male [55.0%]) were compared with 200 control patients (median age, 56 years [range, 14-87 years]; 105 male [52.5%]), and the Glioma Index was constructed using 3 microRNAs (miR-4763-3p, miR-1915-3p, and miR-3679-5p). In validation set 1, the AUC was 0.99 (95% CI, 0.99-1.00); sensitivity, 0.95 (95% CI, 0.89-1.00); and specificity, 0.97 (95% CI, 0.93-1.00). The Glioma Index classified 39 of 42 PCNSL samples (92.9%) and 25 of 28 metastatic brain tumor samples (89.3%) as positive and 2 of 2 spinal tumors (100%) as negative in the exploratory set. In training set 2, 68 patients with GBM, 34 with PCNSL, and 23 with metastatic brain tumor were compared, and the 3-Tumor Index was constructed using 48 microRNAs. The 3-Tumor Index had an accuracy of 0.80, positively detecting 16 of 17 GBM samples (94.1%), 4 of 5 metastatic brain tumor samples (80.0%), and 4 of 8 PCNSL samples (50.0%) in validation set 2. <h3>Conclusions and Relevance</h3> This study appears to have identified promising serum microRNA combinations for detecting diffuse glioma and for assessing histologic features of brain tumors.
Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma Progression
Authors: Amina Boussouar, Antonin Tortereau, Ambroise Manceau, Andrea Paradisi, Nicolas Gadot, Jonathan Vial, David Neves, Lionel Larue, Maxime Battistella, Christophe Leboeuf, Celeste Lebbé, Anne Janin, Patrick Mehlen
Journal: Cancer Research (2019)

Deleted in colorectal cancer (DCC), the receptor for the multifunctional cue netrin-1, acts as a tumor suppressor in intestinal cancer and lung metastasis by triggering cancer cell death when netrin-1 is lowly expressed. Recent genomic data highlighted that DCC is the third most frequently mutated gene in melanoma; we therefore investigated whether DCC could act as a melanoma tumor suppressor. Reexpressing DCC in human melanoma cell lines promoted tumor cell death and tumor growth inhibition in xenograft mouse models. Genetic silencing of DCC prodeath activity in a BRAFV600E mouse model increased the proportion of mice with melanoma, further supporting that DCC is a melanoma tumor suppressor. Netrin-1 expression was elevated in melanoma compared with benign melanocytic lesions. Upregulation of netrin-1 in the skin cells of a BRAFV600E-mutated murine model reduced cancer cell death and promoted melanoma progression. Therapeutic antibody blockade of netrin-1 combined with dacarbazine increased overall survival in several mouse melanoma models. Together, these data support that interfering with netrin-1 could be a viable therapeutic approach in patients with netrin-1-expressing melanoma. SIGNIFICANCE: Netrin-1 and its receptor DCC regulate melanoma progression, suggesting therapeutic targeting of this signaling axis as a viable option for melanoma treatment.
Functional Genomics of the Platelet ADP and Collagen Signalling Pathways.
Authors: Stephen F Garner, Chris I Jones, Jonathan Stephens, Sarah L Bray, Will Angenent, Philippa Burns, Richard W Farndale, Catherine Rice, Frank Dudbridge, Nick Watkins, Bernard de Bono, Panos Deloukas, Alison H Goodall, Willem Ouwehand
Journal: Blood (2008)
Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.
Authors: Jennifer R. Brown, Iryna Rastarhuyeva, Jyothi Jagannathan, Kristen Stevenson, Donna Neuberg, Yulia Melenevsky, Kimberly S. Phillips, Jennifer C. Clark, Ronald W. Takvorian, David C. Fisher, Arnold S. Freedman, Annick D. Van den Abbeele
Journal: Blood (2007)
Neural Interfaces: An Injectable Neural Stimulation Electrode Made from an In‐Body Curing Polymer/Metal Composite (Adv. Healthcare Mater. 23/2019)
Authors: James K. Trevathan, Ian W. Baumgart, Evan N. Nicolai, Brian A. Gosink, Anders J. Asp, Megan L. Settell, Shyam R. Polaconda, Kevin D. Malerick, Sarah K. Brodnick, Weifeng Zeng, Bruce E. Knudsen, Andrea L. McConico, Zachary Sanger, Jannifer H. Lee, Johnathon M. Aho, Aaron J. Suminski, Erika K. Ross, Jose L. Lujan, Douglas J. Weber, Justin C. Williams, Manfred Franke, Kip A. Ludwig, Andrew J. Shoffstall
Journal: Advanced Healthcare Materials (2019)

The Injectrode is an in-body curing material that forms an electrode contact with nerves to enable minimally-invasive neuromodulation. The artwork depicts the spirit of Kip A. Ludwig's, Andrew J. Shoffstall's, and co-workers' effort in article number 1900892; to bridge electrical pulses from the outside of the body to nerves on the inside. In this case, a representation of the vagus nerve.
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
Authors: Irina Velikyan, Olof Eriksson
Journal: Theranostics (2019)

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor.The review covers chemistry, preclinical, and clinical evaluation.Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.
The In-Vivo Level of Imatinib Induced Kinase Inhibition Achieved in De-Novo CML Patients during the First 28 Days of Therapy Is a Powerful Predictor of Molecular Outcome.
Authors: Deborah L. White, Verity A. Saunders, Susan Branford, Kevin Lynch, L. Bik To, Timothy P. Hughes
Journal: Blood (2005)
Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition
Authors: Julie Voeller, Amy K. Erbe, Jacob Slowinski, Kayla Rasmussen, Peter M. Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen D. Gillies, Ravi B. Patel, Alvin Farrel, Jo Lynne Rokita, John Maris, Jacquelyn A. Hank, Zachary S. Morris, Alexander L. Rakhmilevich, Paul M. Sondel
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Unlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care treatment for pediatric patients with high-risk neuroblastoma, overall survival remains poor. In a mouse melanoma model, we found that radiation and tumor-specific immunocytokine generate an in situ vaccination response in syngeneic mice bearing large tumors. Here, we tested whether a novel immunotherapeutic approach utilizing radiation and immunocytokine together with innate immune stimulation could generate a potent antitumor response with immunologic memory against syngeneic murine neuroblastoma. <h3>Methods</h3> Mice bearing disialoganglioside (GD2)-expressing neuroblastoma tumors (either NXS2 or 9464D-GD2) were treated with radiation and immunotherapy (including anti-GD2 immunocytokine with or without anti-CTLA-4, CpG and anti-CD40 monoclonal antibody). Tumor growth, animal survival and immune cell infiltrate were analyzed in the tumor microenvironment in response to various treatment regimens. <h3>Results</h3> NXS2 had a moderate tumor mutation burden (TMB) while N-MYC driven 9464D-GD2 had a low TMB, therefore the latter served as a better model for high-risk neuroblastoma (an immunologically cold tumor). Radiation and immunocytokine induced a potent in situ vaccination response against NXS2 tumors, but not in the 9464D-GD2 tumor model. Addition of checkpoint blockade with anti-CTLA-4 was not effective alone against 9464D-GD2 tumors; inclusion of CpG and anti-CD40 achieved a potent antitumor response with decreased T regulatory cells within the tumors and induction of immunologic memory. <h3>Conclusions</h3> These data suggest that a combined innate and adaptive immunotherapeutic approach can be effective against immunologically cold syngeneic murine neuroblastoma. Further testing is needed to determine how these concepts might translate into development of more effective immunotherapeutic approaches for the treatment of clinically high-risk neuroblastoma.
Control of Residual Disease in Imatinib Treated Chronic Myeloid Leukemia Patients with Peptide Vaccinations: 2 Years Follow up of CMLVAX100 Trial.
Authors: Monica Bocchia, Elisabetta Abruzzese, Micaela Ippoliti, Maria Teresa Pirrotta, Malgorzata M. Trawinska, Marilina Amabile, Giovanni Martinelli, Francesco Forconi, Alessandro Gozzetti, Angelo M. Carella, Donatella Raspadori, Francesco Lauria
Journal: Blood (2005)
The Efficacy of Histone Deacetylase Inhibitor, Vorinostat against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Monotherapy and in Combination with Dasatinib
Authors: Seiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki, Eishi Ashihara
Journal: Blood (2008)
Deficiency of CUX1, Encoded on 7q, Blocks the Normal HSC DNA Damage Response and Drives Highly Penetrant Therapy-Related Myeloid Neoplasms in Mice
Authors: Molly K Imgruet, Ningfei An, Saira Khan, Julian K Lutze, Bonnie Hu, Stephen J. Kron, Sandeep Gurbuxani, Megan E. McNerney
Journal: Blood (2019)
关于酒精的知识（一）：身体内的酒精
Authors: 夏志伟
Journal: BMJ (2005)

酒精(即乙醇)是一种药物，作为医疗卫生工作者，应该了解其对人体生理机能的影响及其致病作用，电应了解乙醇在人体内的代谢过程。乙醇为可溶于水的小分子．在胃内吸收较慢．但在小肠中吸收较快．可分布到身体各个部位。酒精可提供大量热卡，6品脱啤酒含500卡；半升威士忌含1650卡。而一个中等活动量的男性每日需3000卡，女性仅需2200卡。
Heart Failure Improvement after Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation.
Authors: Antonio A. Carrasco-Yalan, Roberto Fernandez-Viña, Jorge Castillo-Aguirre, Hugo Rios, Marco Alvarez, R. de Moura, C. Cruz, A. Carrillo, S. Chirinos, E. Ercilla, A. Patel, Jorge Tumak-Mubarak
Journal: Blood (2007)
Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort
Authors: Clementina López-Medina, Anna Molto, Pascal Claudepierre, Maxime Dougados
Journal: Annals of the Rheumatic Diseases (2019)

Objectives To compare the clinical manifestations, disease activity and disease burden between patients with radiographic (r-axSpA) and non-radiographic axial spondyloarthritis (nr-axSpA) over a 5-year follow-up period in the Devenir des Spondylarthropathies Indifferénciées Récentes (DESIR) cohort. Methods Patients from the DESIR cohort who had X-ray images of the sacroiliac joints available at baseline and did not leave the study during the 5-year follow-up period because of a diagnosis other than axSpA were included. A unilateral rating of ‘obvious sacroiliitis’ by the local reader was considered sufficient for classification as r-axSpA. The incidence of first episodes of peripheral and extra-rheumatic manifestations was compared between the two groups using the incidence rate ratio and Cox regressions adjusted for sex, age and tumour necrosis factor blocker (TNFb) intake. Mean values of patient-reported outcomes (PROs) and days of sick leave over 5 years of follow-up were compared using mixed models adjusted for sex, age, TNFb intake and baseline values. Results In total, 669 patients were included, of whom 185 (27.7%) and 484 (72.3%) were classified as r-axSpA and nr-axSpA, respectively. At baseline, the r-axSpA patients showed a significantly higher prevalence of males. After adjusting for age, sex and TNFb intake, Cox regressions for peripheral and extra-rheumatic manifestations did not show any significant differences between groups. Mixed models also showed similar mean levels in PROs and days of sick leave between groups over time. Conclusion The incidence of peripheral and extra-rheumatic manifestations as well as the disease burden over time remained similar between r-axSpA and nr-axSpA groups after adjusting for intermediate variables. Trial registration number NCT01648907
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Authors: Marc Arbyn, Elisabete Weiderpass, Laia Bruni, Silvia de Sanjosé, Mona Saraiya, Jacques Ferlay, Freddie Bray
Journal: The Lancet Global Health (2019)

The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative.
Secondary Amenorrhoea after Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives during Therapy: A Report from the German Hodgkin Lymphoma Study Group (GHSG).
Authors: Karolin Behringer, Kai Breuer, Thomas Reineke, Michael May, Lucia Nogova, Beate Klimm, Volker Diehl, Andreas Engert
Journal: Blood (2004)
Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies.
Authors: Julie Cote, Olivier Dumas, Christine Demers, Julie Lemieux
Journal: Journal of Clinical Oncology (2013)

e17517 Background: Tunnelled catheters (Leonard, BARD) and peripherally inserted central catheters (Piccline, BARD) are used for intravenous therapies in patients with malignancies. Thrombosis is a well known complication, but risk factors are not clearly established. The objective the incidence, risk factors, therapeutic approaches and complications of catheter-related thrombosis among patients with malignancies. Methods: Medical charts of patients with malignancies and Leonard or Piccline inserted, from August 2002 to December 2006 at Hôpital de l’Enfant-Jésus (Québec City, Canada), were retrospectively reviewed. Results: A total of 618 catheters were inserted in 361 patients. Eighty-six percent of the catheters were placed in patients with hematologic malignancies and most were Piccline (70%). Sixty-one thromboses were identified (incidence of 10%). Fourteen percent of the patients had more than one episode of catheter-related thrombosis. The majority of thromboses was related to a Piccline (93%) and occurred at a mean time of 34 days after the insertion. At the time of thrombosis, the mean platelet count was 169 x 10 9 /L. Previous history of a catheter-related thrombosis (OR = 4.30 (1.48-12.50); p = 0.0075) as well as lymphoma (OR = 3.29 (1.22-8.87); p = 0.0185) were associated with superficial thromboses. The Piccline was associated with both types of thromboses (OR = 5.78 (1.69-19.74); p = 0.0051), especially with superficial thromboses. Most of the catheters (88%) were removed once a thrombosis was identified. The management of anticoagulation varied considerably. No complication associated with thromboses was reported. Conclusions: The incidence of central venous catheter-related thrombosis was 10%. The thrombosis occurred on average 34 days after the insertion. The Piccline was associated with all types of thromboses, especially the superficial ones. A previous history of catheter-related thrombosis and lymphoma were risk factors for superficial thromboses. Further studies are necessary to better define characteristics and optimal management of central catheter-related thrombosis.
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling
Authors: Tom Hofland, Sanne Endstra, Calum K.P. Gomes, Renate de Boer, Iris de Weerdt, Vladimir Bobkov, Jurgen A. Riedl, Raimond Heukers, Martine J. Smit, Eric Eldering, Mark-David Levin, Arnon P. Kater, Sanne H. Tonino
Journal: HemaSphere (2019)

Abstract Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction, which may underlie the hampered efficacy of cellular immunotherapy. Most data on dampened immune responses in CLL come from studies investigating CLL and T cell interactions. Natural killer (NK) cells may be an attractive alternative source of effector cells in immunotherapy in CLL, provided that functionality is retained within the CLL micro-environment. Despite their important role in anti-tumor responses, NK cells are not extensively characterized in CLL. Here, we studied the expression of activating and inhibitory receptors on CLL-derived and healthy control (HC) NK cells, and their functional response towards several stimuli. NK cells from CLL patients have an increased maturation stage, with an expansion of NKG2C + NK cells in CMV seropositive individuals. The cytotoxicity receptor NKG2D is downregulated, and the killing capacity through this receptor was markedly reduced in CLL-derived NK cells. In contrast, activation via CD16 (FCγRIII) led to adequate activation and functional responses in CLL-derived NK cells. These findings indicate that NK cells in CLL are not intrinsically defect and still perform effector functions upon adequate activating signaling. Clinical relevance of this finding was shown by treatment with novel nanobody-Fc constructs, which induced cytotoxic responses in both CLL- and HC-derived NK cells via CD16. Our results show that NK cells, in contrast to the T cell compartment, retain their function within the CLL micro-environment, provided that they receive an adequate activating signal. These findings warrant future studies on NK cell mediated immunotherapeutic strategies in CLL.
Addressing Knowledge Gaps in Acute Myeloid Leukemia to Improve Referral for Hematopoietic Cell Transplantation Consultation
Authors: Christa Meyer, Lih-Wen Mau, Elizabeth A. Murphy, Ellen M. Denzen, Ellyce Hayes, Darlene Haven, Heather Moore, Jackie Foster, Jaime M. Preussler, Linda J. Burns
Journal: Journal of the National Comprehensive Cancer Network (2019)

Outcomes after hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) are better when HCT is performed during first complete remission (CR1). This study aimed to identify and address knowledge gaps that affect the timely referral of patients for HCT consultation.A mixed-methods educational needs assessment included a national survey and focus groups consisting of hematologists/oncologists. An educational intervention of 3 webinars addressed identified knowledge gaps.A total of 150 hematologists/oncologists were recruited for the survey, of whom 20 participated in focus groups. Physicians in practice 0 to 10 years were 4.2 times more likely to refer for HCT consultation in CR1 than those with >10 years in practice (P=.0027). Physicians seeing ≤10 patients with AML in the past year were 3.7 times more likely to refer for HCT consultation in CR1 than those seeing >10 patients (P=.0028). Knowledge gaps included (1) improper classification of molecular/cytogenetic results for risk stratification, (2) lack of understanding that disease stage impacts outcomes, and (3) use of chronologic age alone for referral decision-making. Combined attendance for the webinars was 1,098 clinicians; >74% of participants indicated that they would apply the knowledge they gained in clinical practice. Trends were observed toward improvement in identifying favorable-risk AML, from 48% to 60% (n=85; P=.12); improvement in identifying 2 poor-risk cytogenetic/molecular abnormalities, with the percentage of respondents indicating chromosome 7 deletion increasing from 51% to 70% (n=53; P=.05) and that of respondents indicating TP53 mutation increasing from 42% to 62% (n=62; P=.03); and improvement in identifying which patients with AML aged >60 years were most likely to benefit from HCT based on cytogenetic/molecular features, with the percentage of correct responses increasing from 66% to 81% (n=62; P=.07).The webinars met the educational needs of learners and improved knowledge gaps. This study provided novel insights into the learning needs of clinicians who care for patients with AML and a roadmap for future educational interventions.
No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial
Authors: Filippo Milano, Andrew R Rezvani, Joanne Kurtzberg, Chatchada Karanes, Jonathan A Gutman, Christine Duncan, Alla Keyzner, Rabi Hanna, Tonya Kimberly Marmon, Ann Dahlberg, Colleen Delaney
Journal: Blood (2019)